Skip to content

Merck launches expanded access programme for integrase inhibitor

Darunavir/ritonavir superior virologically and immunologically to comparator drugs over one year

Selenium improves ART response in Nigerian randomised study

Warning issued over bleeding within the skull in patients taking tipranavir

US activists 'applaud' darunavir (Prezista, TMC114) pricing

Darunavir (TMC114) approved for use in treatment-experienced patients in US

Better than expected 'real world' benefits seen in highly treatment-experienced patients on atazanavir

Conflicting pharmacokinetic results when lopinavir and atazanavir are double-boosted with ritonavir

European HIV Drug Resistance Workshop: clinical implications of resistance